Publications by authors named "Daria Burnes"
Article Synopsis
- The COVID-19 pandemic caused a major global health and economic crisis, with vaccinations (CV) being crucial for recovery, yet their overall global value is not well-documented.
- Researchers conducted regression analyses to assess how CV impacted GDP, infections, and deaths, estimating value through QALY gains, cost savings, and GDP effects across 148 countries from January 2020 to December 2021.
- The total global value of CV was estimated at $5.2 trillion, with Pfizer-BioNTech vaccines contributing over $1.9 trillion; CV provided significant economic and health benefits, indicating strong value for money and important macrosocial gains.
Cost-utility and cost-benefit analysis of pediatric PCV programs in Egypt.
Hum Vaccin Immunother
November 2022
New vaccine introductions (NVIs) raise issues of value for money (VfM) for self-financing middle-income countries like Egypt. We evaluate a pediatric pneumococcal conjugate vaccine (PCV) NVI in Egypt from health payer and societal perspectives, using cost-utility and cost-benefit analysis (CUA, CBA). We evaluate vaccinating 100 successive birth cohorts with the 13-valent PCV ("PCV13") and the 10-valent PCV ("PCV10") relative to no vaccination and each other.
View Article and Find Full Text PDFProductivity benefits of health technologies are ignored in typical economic evaluations from a health payer's perspective, risking undervaluation. We conduct a productivity-based cost-benefit analysis from a societal perspective and estimate indirect costs of adult pneumococcal disease, vaccination benefits from the adult 13-valent pneumococcal conjugate vaccine (PCV13 Adult), and rates of return to PCV13 Adult for a range of hypothetical vaccination costs. Our context is Turkey's funding PCV13 for the elderly and for non-elderly adults with select comorbidities within the Ministry of Health's National Immunization Program.
View Article and Find Full Text PDF